Your HCV s/co (signal-to-cutoff) ratio is a number generated by the antibody screening test used to check for hepatitis C virus exposure. It is not a simple positive or negative but rather a measure of how strongly your blood sample reacted compared to a built-in threshold. A ratio at or above 1.0 is considered “reactive,” meaning the test detected something worth investigating, but the size of that number matters enormously. A low reactive result, say between 1.0 and 3.0, has a high chance of being a false positive, while a very high ratio above 10 or 20 strongly suggests true HCV exposure. The critical thing to understand is that this screening result alone does not tell you whether you are infected right now.
What the Number Actually Represents
Every antibody screening test has an internal reference value, the “cutoff.” The test measures how much signal your blood sample produces compared to that reference. If your sample produces a signal equal to the cutoff, you get an s/co of 1.0, the bare minimum to count as reactive. If it produces ten times the signal, your s/co is 10.0. The test is essentially measuring how much antibody-like activity it found in your blood, and expressing it as a ratio.
This is where the confusion starts: the test detects antibodies to HCV, not the virus itself. Antibodies can be present because you are currently infected, because you were infected in the past and cleared the virus (either on your own or with treatment), or because the test is reacting to something in your blood that isn’t actually an HCV antibody at all. The s/co ratio helps sort out which of these scenarios is most likely, but it cannot do it alone.
Low Ratios and the False-Positive Problem
If your s/co ratio is low, somewhere between 1.0 and about 3.0, the most likely explanation in many clinical settings is a false positive. Several studies have confirmed this pattern. Research on a large clinical dataset found that an s/co below 3.0 ruled out active HCV infection and prior exposure with 100% negative predictive value.1Clinical Chemistry. Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay Another study examining specimens with low s/co ratios found that these were commonly negative when tested with supplemental methods or checked for actual viral genetic material.2Clinical Chemistry. Low-Positive Anti-Hepatitis C Virus Enzyme Immunoassay Results: An Important Predictor of Low Likelihood of Hepatitis C Infection
The reason low-reactive results so often turn out to be false alarms is straightforward. Antibody tests are designed to be extremely sensitive so they don’t miss anyone who is truly infected. That sensitivity comes at a cost: the test occasionally reacts to proteins, immunoglobulins, or other substances in your blood that happen to mimic HCV antibodies just enough to push the signal above the cutoff. The weaker that signal, the more likely it was caused by something other than genuine HCV antibodies.
How common are false positives? In a population with low HCV prevalence (around 1%), data from the National Health and Nutrition Examination Survey found that roughly three out of every ten reactive screening results were false positives or indeterminate, with most indeterminate results also likely false.3PubMed Central. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007–2012 In populations where HCV is more common, such as among people who inject drugs, the rate of false positives drops substantially because a higher proportion of reactive results reflect real infections.
High Ratios and What They Suggest
When your s/co ratio is high, the picture changes. Research across different labs and assay platforms has identified thresholds above which a true positive becomes very likely, though the exact number depends on which testing system your lab uses. One large study found that an s/co of 10.3 was the most efficient cutoff point for reliably predicting true HCV antibody status.4PubMed Central. Role of signal-to-cutoff ratios in hepatitis C virus antibody detection A Korean study identified an s/co of 10.9 as a highly accurate predictor of active viral infection, with sensitivity above 94% and specificity above 97%.5PubMed Central. Significance of anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia
At even higher ratios, confidence increases further. When the s/co hit 20 or above, one study found a positive predictive value of nearly 99% when compared with supplemental antibody testing.1Clinical Chemistry. Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay A study comparing anti-HCV results with actual viral RNA detection found that patients with detectable virus had median s/co values around 13.4, while those who were antibody-reactive but RNA-negative had median values under 2.0.6PubMed. Comparison of Anti HCV Signal-to-Cutoff Ratio with HCV RNA Results
A high s/co, however, still doesn’t tell you with certainty that the virus is active in your body right now. It tells you that you almost certainly have been exposed. Some people clear HCV spontaneously, and their antibodies can remain at high levels for a period after the virus is gone. This is one of several reasons a follow-up test is essential.
Why There Is No Single “Magic Number”
If you’ve been reading carefully, you may have noticed that the threshold numbers differ across studies: 3.0, 10.3, 10.9, 20.0. This isn’t sloppy science. Different laboratories use different testing platforms made by different manufacturers, and each platform has its own internal calibration. An s/co of 5 on one machine doesn’t mean the same thing as an s/co of 5 on another. Research from India using enzyme immunoassays found that sensitivity and positive predictive value reached 100% at an s/co of 3.0 to 4.0 on their platform, with specificity improving above 4.5.7PubMed Central. Role of signal-to-cut-off ratios of anti-hepatitis C virus antibody by enzyme immunoassays along with ID-NAT for screening of whole blood donors in India A separate analysis using a different assay system found that an s/co of about 3.1 predicted positivity with 95% probability, while an s/co of roughly 8.9 corresponded to only a 50% probability of positivity.8PubMed. Signal-to-cutoff ratios of current anti-HCV assays and a suggestion of new algorithm of supplementary testing That second finding might seem counterintuitive, but it reflects how different assays weight their signals and set their cutoff levels differently.
This variability is why your doctor or lab report will not simply say “your ratio is above X, so you’re positive.” The ratio is one piece of information that feeds into a broader testing sequence. What it can do reliably across platforms is help prioritize: very low ratios are almost certainly false alarms, very high ratios almost certainly reflect real antibody presence, and the gray zone in between needs further testing to resolve.
The RNA Test Is What Settles It
Regardless of your s/co ratio, the definitive next step after a reactive antibody screen is an HCV RNA test, also called a nucleic acid test or NAT. This test looks for the virus’s actual genetic material in your blood. If RNA is detected, you have an active, current infection. If RNA is not detected, you either cleared the virus on your own, were treated and cured in the past, or the antibody result was a false positive.
The importance of this follow-up step cannot be overstated, and historically it has been a weak link in the diagnostic process. CDC data show that when RNA testing required a separate lab order or a return visit, only about 62% to 68% of patients completed the testing sequence.9Centers for Disease Control and Prevention (MMWR). Updated Operational Guidance for Implementing CDC’s Recommendations on Testing for Hepatitis C Virus Infection That means roughly a third of people with a reactive antibody screen never found out whether they actually had the virus. When healthcare systems switched to automatic “reflex” testing, where the same blood sample is sent for RNA testing without requiring a new order or visit, completion rates jumped dramatically, reaching 85% to 98%.
This shift toward reflex testing is now widely recommended. A laboratory-based analysis confirmed that reflex RNA testing improves completion of confirmatory testing and reduces unnecessary repeat antibody testing.10PubMed Central. Missed confirmatory HCV RNA testing in anti-HCV-reactive patients and the role of reflex testing in improving completion of the hepatitis C diagnostic care cascade If your lab used reflex testing, the RNA result may already be on its way before you even see the antibody result. If not, ask your provider to order one promptly.
It’s worth noting that the old supplemental test used to confirm antibody results, the recombinant immunoblot assay (RIBA), was discontinued in 2011. Before that, RIBA served as a middle step between screening and RNA testing. Evaluation of diagnostic performance before and after RIBA’s removal found that dropping it had no significant effect on the accuracy of HCV identification, as long as the antibody s/co ratio was considered in deciding next steps.11PubMed Central. Evaluation of Quantitative Real-Time PCR as a Hepatitis C Virus Supplementary Test After RIBA Discontinuation Today, the pathway goes directly from antibody screen to RNA testing.
Who Gets False Positives and Why
Certain conditions and situations make false-positive antibody results more likely. Understanding these can help you interpret your result in context, especially if your s/co ratio falls in the low-to-moderate range.
- Autoimmune hepatitis: People with this condition frequently test positive on HCV antibody screens despite having no actual HCV infection. The culprit appears to be the high levels of immunoglobulin in their blood, which can bind weakly in the assay and generate a false signal.12Mayo Clinic Proceedings. The Diagnosis and Management of Chronic Hepatitis Early studies confirmed that most positive HCV antibody results in autoimmune hepatitis patients are false, as viral RNA is usually absent.13PubMed. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis
- High bilirubin, protein, or immunoglobulin levels: Any condition that raises these substances in the blood can cause assay interference, producing reactive results that don’t reflect true HCV antibodies.14The Journal of Applied Laboratory Medicine. A Pregnant Patient with a Positive Hepatitis C Antibody
- Other infections: Hepatitis A, HIV, and potentially other viral infections have been associated with false-positive HCV antibody tests.
- Heterophilic antibodies: These are unusual antibodies some people produce that can interfere with lab assays in unpredictable ways, sometimes triggered by exposure to animal proteins or certain medical treatments.
- Pregnancy: Pregnant individuals can have altered immune profiles that increase the chance of nonspecific antibody reactivity.
Low prevalence settings also amplify the false-positive problem, as noted earlier. When HCV is uncommon in the population being screened, even a very good test will generate a noticeable proportion of false alarms simply because there are so many more uninfected people being tested. In higher-prevalence populations, the math shifts and a reactive result is much more likely to reflect true infection.15Scientific Reports. The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations
When Antibody Tests Miss Real Infections
False positives get most of the attention, but false negatives also occur, and they carry different risks. There are two main scenarios where someone infected with HCV can have a negative or nonreactive antibody screen.
The first is the “window period.” After initial infection, the immune system takes time to produce detectable antibodies. During this gap, an antibody test will read negative even though the virus is actively replicating. Research using combined antigen-antibody assays found that these newer tests could detect infection an average of about 22 days before the most sensitive antibody-only assays turned positive.16PubMed Central. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection If you had a known recent exposure to HCV and tested antibody-negative, your provider may recommend retesting in a few weeks or going directly to RNA testing.
The second scenario involves people with weakened immune systems. Individuals who are immunosuppressed, including those on dialysis, transplant recipients, and people living with HIV, may fail to produce enough antibodies for the screening test to detect, even while carrying active HCV infection.17PubMed Central. Seronegative hepatitis C virus infection In one study of HCV-seronegative dialysis patients who had unexplained liver enzyme abnormalities, RNA testing revealed occult HCV infections in about 31% of them.18PubMed Central. Impact of isolated hepatitis C virus (HCV) core-specific antibody detection and viral RNA amplification among HCV-seronegative dialysis patients at risk for infection For people in these groups, an s/co ratio of zero does not reliably rule out HCV, and direct RNA testing is the safer diagnostic approach.
What Happens to Your Antibody Levels After Clearance
One common source of confusion is people who cleared HCV in the past, either spontaneously or through treatment, and then test antibody-positive years later. This is expected. HCV antibodies persist after the virus is gone, sometimes for decades. Your s/co ratio in this situation can range from moderately elevated to quite high, depending on when you cleared the virus and your individual immune response.
Research tracking patients with acute hepatitis C who cleared the virus on their own found that antibody levels did decline after spontaneous clearance, but they remained detectable.19PubMed Central. Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil The decline was measurable over months but did not drop to zero. This means that if you were successfully treated for HCV, future antibody screening tests will likely still come back reactive, potentially with a high s/co ratio. You are not reinfected; the test is simply detecting leftover immune memory. The RNA test will confirm no active virus is present.
This is particularly relevant given the expansion of universal HCV screening recommendations. As more people get tested regardless of known risk factors, clinicians are encountering more patients with antibody-positive, RNA-negative results. Having documentation of prior treatment and cure can save you from unnecessary anxiety and repeat testing when you encounter a new healthcare provider.
Treatment Has Transformed the Outlook
If your s/co ratio is high and your RNA test comes back positive, the news is much better than it would have been a decade ago. Modern direct-acting antiviral medications cure HCV in the vast majority of cases. In real-world treatment data from varied clinical settings, sustained virological response rates, meaning the virus remains undetectable at least 12 weeks after finishing treatment, generally exceed 90%.20PubMed Central. Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea Treatment courses are typically 8 to 12 weeks of oral medication, a dramatic improvement over older interferon-based regimens that lasted months and caused significant side effects.
Even among people with compromised immune systems, including transplant recipients and those on immunosuppressive drugs, these antiviral treatments achieve cure rates above 90%.21PubMed Central. Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes This is worth knowing because immunosuppressed individuals are among those most likely to have atypical screening results, whether false negatives from weak antibody responses or true positives discovered through non-routine testing.
Practical Steps When You Get Your Result
If you’re staring at a lab report with an s/co ratio and wondering what to do, here is how the process typically works in practice:
- S/co below 1.0: The test is nonreactive. No further testing is needed unless you had a very recent exposure within the past few weeks, in which case your provider may suggest retesting later or ordering a direct RNA test.
- S/co between 1.0 and about 3.0: Reactive, but the probability of a true positive is low. An RNA test should follow. Expect a good chance it will come back negative, particularly if you have no known risk factors for HCV.
- S/co in the mid-range (roughly 3 to 10): This is the gray zone where the result could go either way depending on the assay platform. RNA testing is essential.
- S/co above 10 to 20: Strongly suggests genuine HCV antibody presence. RNA testing will determine whether the infection is currently active.
In every reactive scenario, the RNA test is the step that matters for your medical decisions. The antibody screen with its s/co ratio is a sorting tool, an efficient way to decide who needs further evaluation. It was never designed to be the final word.
One last practical note: if reflex testing was not performed automatically, don’t let this fall through the cracks. The gap between antibody screening and confirmatory RNA testing has historically been the place where patients get lost in the system. Ask for the RNA test at the same visit, or confirm it’s already been ordered on the same sample. Getting a clear answer sooner rather than later saves weeks of uncertainty and ensures that if treatment is needed, it can start without delay.